Abstract
Objective
To provide a modern overview for radiologists of the unique radiological, pathological, and clinical features of uterine carcinosarcoma (UCS).
Results
UCS is a unique gynecological malignancy that continues to present diagnostic and therapeutic challenges to the field of oncology. The classification and clinical understanding of this malignancy have evolved in recent years, yielding a modern conceptualization of a neoplastic entity that has been well studied but incompletely understood. As UCS causes a significant proportion of deaths secondary to uterine cancer, develo** a familiarity with the imaging and clinical features of this entity is critical. In addition to summarizing the modern understanding of this tumor variant, an overview of the common imaging features of UCS will be presented. The role of radiological staging, imaging findings on presentation and follow-up imaging, and modern treatment paradigms will be discussed. Lastly, the current treatment paradigms and surveillance recommendations for UCS will be summarized.
Conclusion
Knowledge of the modern understanding of uterine carcinosarcoma, including its relevant imaging and clinical features, is critical for radiologists.
Similar content being viewed by others
References
Cantrell LA, Blank S V, Duska LR. Uterine carcinosarcoma: A review of the literature. Gynecol Oncol [Internet]. 2015 Jun 1;137(3):581–8. Available from: https://doi.org/10.1016/j.ygyno.2015.03.041
Singh R. Review literature on uterine carcinosarcoma. J Cancer Res Ther. 2014;10(3):461–8.
Schiavone MB, Zivanovic O, Zhou Q, Leitao MMJ, Levine DA, Soslow RA, et al. Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Map**. Ann Surg Oncol. 2016 Jan;23(1):196–202.
Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017 Mar;31(3):411–23.
Ashley CW, Da Cruz Paula A, Kumar R, Mandelker D, Pei X, Riaz N, et al. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. Gynecol Oncol. 2018;(xxxx):1–9.
McConechy MK, Hoang LN, Chui MH, Senz J, Yang W, Rozenberg N, et al. In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. J Pathol Clin Res. 2015 Jul;1(3):173–85.
Arend R, Doneza JA, Wright JD. Uterine carcinosarcoma. Curr Opin Oncol. 2011 Sep;23(5):531–6.
Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T, et al. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. Int J Clin Oncol. 2016;21(1):168–76.
Kurnit KC, Previs RA, Soliman PT, Westin SN, Klopp AH, Fellman BM, et al. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2018;152(1).
Inoue A, Yamaguchi K, Kurata Y, Murakami R, Abiko K, Hamanishi J, et al. Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. J Gynecol Oncol. 2017;28(5):1–10.
Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, et al. Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2016 Oct;113(43):12238–43.
Dickson EL, Vogel RI, Gehrig PA, Pierce S, Havrilesky L, Secord AA, et al. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. Gynecol Oncol. 2015 Nov;139(2):275–82.
Tirumani SH, Ojili V, Shanbhogue AKP, Fasih N, Ryan JG, Reinhold C. Current concepts in the imaging of uterine sarcoma. Abdom Imaging. 2013;38(2):397–411.
Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: A SEER analysis. Gynecol Oncol. 2008;111(1):82–8.
Kanthan R, Senger J-L. Uterine Carcinosarcomas (Malignant Mixed Müllerian Tumours): A Review with Special Emphasis on the Controversies in Management. Obstet Gynecol Int. 2011;2011:1–13.
Pradhan TS, Stevens EE, Ablavsky M, Salame G, Lee YC, Abulafia O. FIGO staging for carcinosarcoma: Can the revised staging system predict overall survival? Gynecol Oncol. 2011;123(2):221–4.
Takahashi M, Kozawa E, Tanisaka M, Hasegawa K, Yasuda M, Sakai F. Utility of histogram analysis of apparent diffusion coefficient maps obtained using 3.0T MRI for distinguishing uterine carcinosarcoma from endometrial carcinoma. J Magn Reson Imaging. 2016;43(6):1301–7.
Koh W-J, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Feb;16(2):170–99.
Ho K-C, Lai C-H, Wu T-I, Ng K-K, Yen T-C, Lin G, et al. 18F-fluorodeoxyglucose positron emission tomography in uterine carcinosarcoma. Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):484–92.
Freeman SJ, Aly AM, Kataoka MY, Addley HC, Reinhold C, Sala E. The Revised FIGO Staging System for Uterine Malignancies: Implications for MR Imaging. RadioGraphics. 2012;32(6):1805–27.
Akin EA, Kuhl ES, Zeman RK. The role of FDG-PET/CT in gynecologic imaging: an updated guide to interpretation and challenges. Abdom Radiol. 2018;43(9):2474–86.
Lee HJ, Park JY, Lee JJ, Kim MH, Kim DY, Suh DS, et al. Comparison of MRI and18F-FDG PET/CT in the preoperative evaluation of uterine carcinosarcoma. Gynecol Oncol. 2016;140(3):409–14.
Lewin SN. Revised FIGO staging system for endometrial cancer. Clin Obstet Gynecol. 2011 Jun;54(2):215–8.
Teo SY, Babagbemi KT, Peters HE, Mortele KJ. Primary malignant mixed mullerian tumor of the uterus: findings on sonography, CT, and gadolinium-enhanced MRI. AJR Am J Roentgenol. 2008 Jul;191(1):278–83.
Kamishima Y, Takeuchi M, Kawai T, Kawaguchi T, Yamaguchi K, Takahashi N, et al. A predictive diagnostic model using multiparametric MRI for differentiating uterine carcinosarcoma from carcinoma of the uterine corpus. Jpn J Radiol. 2017;35(8):472–83.
Genever A V, Abdi S. Can MRI predict the diagnosis of endometrial carcinosarcoma? Clin Radiol [Internet]. 2011 Jul 1;66(7):621–4. Available from: https://doi.org/10.1016/j.crad.2011.02.008
Shih I-L, Shih TT-F. PET/MR hybrid imaging of cervical and endometrial cancer. J Cancer Res Pract [Internet]. 2018;5(3):91–8. Available from: http://www.sciencedirect.com/science/article/pii/S2311300617301118
Kitajima K, Suenaga Y, Ueno Y, Kanda T, Maeda T, Takahashi S, et al. Value of fusion of PET and MRI for staging of endometrial cancer: Comparison with 18F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI. Eur J Radiol [Internet]. 2013 Oct 1;82(10):1672–6. Available from: https://doi.org/10.1016/j.ejrad.2013.05.005
Zwahlen DR, Schick U, Bolukbasi Y, Thariat J, Abdah-Bortnyak R, Kuten A, et al. Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study. Rare Tumors [Internet]. 2016 Jun 29;8(2):6052. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27441069
Shah SH, Jagannathan JP, Krajewski K, O’Regan KN, George S, Ramaiya NH. Uterine sarcomas: Then and now. Am J Roentgenol. 2012;199(1):213–23.
Healy V, O’Halloran P, O’Brien S, Beausang A, Caird J. CNS metastasis secondary to malignant-mixed Müllerian tumor: case report and review of therapeutics. CNS Oncol. 2017/10/09. 2017 Oct;6(4):315–23.
Cantrell LA, Havrilesky L, Moore DT, O’Malley D, Liotta M, Secord AA, et al. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. Gynecol Oncol. 2012;127(1):22–6.
Cha J, Kim YS, Park W, Kim HJ, Kim JY, Kim JH, et al. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: A multicenter retrospective study (KROG 13-08). J Gynecol Oncol. 2016;27(6):1–12.
Kumar Dandamudi R, Aslam S, Walji N, El-Modir A, Fernando I. Chemotherapy for uterine carcinosarcoma with carboplatin, ifosfamide and mesna. Anticancer Res. 2015;35(9):4841–8.
Brackmann M, Stasenko M, Uppal S, Erba J, Reynolds RK, McLean K. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: A single institution case series and review of the literature. BMC Cancer. 2018;18(1):1–7.
Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol. 2009 Mar;112(3):543–52.
Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol. 2000 Nov;79(2):147–53.
Lacour RA, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, et al. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr;21(3):517–22.
Lorusso D, Martinelli F, Mancini M, Sarno I, Ditto A, Raspagliesi F. Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study. Int J Gynecol Cancer. 2014 Sep;24(7):1256–61.
Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol. 2010 Jun;28(16):2727–31.
Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, et al. Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. Gynecol Oncol. 2017;147(3):565–71.
Vitale SG, Laganà AS, Capriglione S, Angioli R, La Rosa VL, Lopez S, et al. Target therapies for uterine carcinosarcomas: Current evidence and future perspectives. Int J Mol Sci. 2017;18(5):1–16.
Makker V, Recio FO, Ma L, Matulonis UA, Lauchle JO, Parmar H, et al. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. 2016 Nov;122(22):3519–28.
Einstein MH, Klobocista M, Hou JY, Lee S, Mutyala S, Mehta K, et al. Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecol Oncol. 2012 Jan;124(1):26–30.
Sozen H, Çiftçi R, Vatansever D, Topuz S, Iyibozkurt AC, Bozbey HU, et al. Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma. Aust New Zeal J Obstet Gynaecol. 2016;56(2):199–206.
GGonzalez Bosquet J, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, et al. The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol. 2010;116(3):419–23.
Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000 Jun;88(12):2782–6.
Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, et al. Clinical utility of CA-125 in the management of uterine carcinosarcoma. Vol. 29, Journal of Gynecologic Oncology. Korea (South); 2018. p. e88.
Funding
Stefanie Avril, MD is supported by the Clinical and Translational Science Collaborative of Cleveland, (CTSCA/KL2 TR0002547). The remaining authors have no disclosures.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ravishankar, P., Smith, D.A., Avril, S. et al. Uterine carcinosarcoma: a primer for radiologists. Abdom Radiol 44, 2874–2885 (2019). https://doi.org/10.1007/s00261-019-02038-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-019-02038-8